Notice Pursuant to the National Cooperative Research and Production Act of 1993-Biopharmaceutical Manufacturing Preparedness Consortium, 26923 [2024-07947]

Download as PDF Federal Register / Vol. 89, No. 74 / Tuesday, April 16, 2024 / Notices VA; University of Houston Systems, Houston, TX; Urban Electric Power, Inc., Pearl River, NY; and, Ward Leonard CT LLC, Thomaston, CT, have withdrawn from this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and UTIC intends to file additional written notifications disclosing all changes in membership. On October 9, 2018, UTIC filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on November 2, 2018 (83 FR 55203). The last notification was filed with the Department on October 6, 2023. A notice was published in the Federal Register pursuant to section 6(b) of the Act on December 15, 2023 (88 FR 86939). Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. [FR Doc. 2024–07937 Filed 4–15–24; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE Antitrust Division khammond on DSKJM1Z7X2PROD with NOTICES Notice Pursuant to the National Cooperative Research and Production Act of 1993—Biopharmaceutical Manufacturing Preparedness Consortium Notice is hereby given that, on January 5, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Biopharmaceutical Manufacturing Preparedness Consortium (‘‘BIOMAP– CONSORTIUM’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties to the venture and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Pursuant to section 6(b) of the Act, the identities of the parties to the venture as of the date of this filing are: Advanced BioSciences Laboratory, Inc., Rockville, MD; Antheia, Inc., Menlo Park, CA; ApiJect Systems America, Inc., Stamford, CT; Applied Materials, Inc., Santa Clara, CA; CAMRIS International LLC, Bethesda, MD; Civica, Inc., Lehi, UT; Clarivate Analytics (US) LLC, Ann VerDate Sep<11>2014 19:09 Apr 15, 2024 Jkt 262001 Arbor, MI; Ginkgo Bioworks, Inc., Boston, MA; Global Life Sciences Solutions USA LLC dba Cytiva, Marlborough, MA; Grand River Aseptic Manufacturing, Inc., Grand Rapids, MI; ImmunityBio, Inc., Culver City, CA; Joint Research and Development (JRAD) LLC, Stafford, VA; Maravai LifeSciences, San Diego, CA; Mission Pharmacal Company, San Antonio, TX; NextBeam LLC, North Sioux City, SD; Northeastern University, Boston, MA; OCUGEN, Inc., MALVERN, PA; Ocyon Bio PR, Inc., Aguadilla, PUERTO RICO; PSC Biotech Corp., Pomona, CA; Regis Technologies, Inc., Morton Grove, IL; Resilience Government Services, Alachua, FL; Riya Interactive, Inc., Chicago, IL; SEQENS, Devens, MA; Sanofi Pasteur, Inc., Swiftwater, PA; Slingshot Biosciences, Inc., Emeryville, CA; Smart World LLC dba Steri-Tek, Fremont, CA; TR Processing LLC, Golden Valley, MN; The Conafay Group, Washington, DC; USAntibiotics LLC, Bristol, TN; Varda Space Industries, Inc., El Segundo, CA. Consistent with 15 U.S.C. 4301(a)(6)(C), (E) and (F), the general areas of BioMaP Consortium’s planned activities are to engage the biopharmaceutical industrial base to enable targeted development expertise, address new and emerging biopharmaceutical technologies that enhance existing capabilities, as well as prepare for potential response to emerging pathogens with pandemic potential. 26923 MD; Kyowa Kirin, Tokyo, JAPAN; and Gru¨nenthal Group, Aachen, GERMANY, have been added as parties to the venture. Also, Medexprim, Labe´ge, FRANCE; Artificial, Inc., Palo Alto, CA; LabVoice, Durham, NC; Labforward GmbH (formerly cubuslab GmbH), Karlsruhe, GERMANY; Semantic Arts, Fort Collins, CO; and Matador Japan KK, Nagano, JAPAN, have withdrawn as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Pistoia Alliance, Inc. intends to file additional written notifications disclosing all changes in membership. On May 28, 2009, Pistoia Alliance, Inc. filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on July 15, 2009 (74 FR 34364). The last notification was filed with the Department on December 20, 2023. A notice was published in the Federal Register pursuant to section 6(b) of the Act on March 13, 2024 (89 FR 18437). Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. [FR Doc. 2024–07987 Filed 4–15–24; 8:45 am] BILLING CODE P Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. DEPARTMENT OF JUSTICE [FR Doc. 2024–07947 Filed 4–15–24; 8:45 am] Notice Pursuant to the National Cooperative Research and Production Act of 1993—National Spectrum Consortium Antitrust Division BILLING CODE P DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—Pistoia Alliance, Inc. Notice is hereby given that, on March 7, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C.§ 4301 et seq. (the ‘‘Act’’), Pistoia Alliance, Inc. filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Mettler Toledo, Columbia, PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 Notice is hereby given that, on January 9, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), National Spectrum Consortium (‘‘NSC’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Sherpa 6, Inc., Littleton, CO; Pseudolithic, Inc., Santa Barbara, CA; Defense Industry Advisors LLC, Dayton, OH; and Radius Method LLC, Boca Raton, FL, have been added as parties to this venture. E:\FR\FM\16APN1.SGM 16APN1

Agencies

[Federal Register Volume 89, Number 74 (Tuesday, April 16, 2024)]
[Notices]
[Page 26923]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-07947]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Biopharmaceutical Manufacturing Preparedness 
Consortium

    Notice is hereby given that, on January 5, 2024, pursuant to 
section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Biopharmaceutical 
Manufacturing Preparedness Consortium (``BIOMAP-CONSORTIUM'') has filed 
written notifications simultaneously with the Attorney General and the 
Federal Trade Commission disclosing (1) the identities of the parties 
to the venture and (2) the nature and objectives of the venture. The 
notifications were filed for the purpose of invoking the Act's 
provisions limiting the recovery of antitrust plaintiffs to actual 
damages under specified circumstances.
    Pursuant to section 6(b) of the Act, the identities of the parties 
to the venture as of the date of this filing are: Advanced BioSciences 
Laboratory, Inc., Rockville, MD; Antheia, Inc., Menlo Park, CA; ApiJect 
Systems America, Inc., Stamford, CT; Applied Materials, Inc., Santa 
Clara, CA; CAMRIS International LLC, Bethesda, MD; Civica, Inc., Lehi, 
UT; Clarivate Analytics (US) LLC, Ann Arbor, MI; Ginkgo Bioworks, Inc., 
Boston, MA; Global Life Sciences Solutions USA LLC dba Cytiva, 
Marlborough, MA; Grand River Aseptic Manufacturing, Inc., Grand Rapids, 
MI; ImmunityBio, Inc., Culver City, CA; Joint Research and Development 
(JRAD) LLC, Stafford, VA; Maravai LifeSciences, San Diego, CA; Mission 
Pharmacal Company, San Antonio, TX; NextBeam LLC, North Sioux City, SD; 
Northeastern University, Boston, MA; OCUGEN, Inc., MALVERN, PA; Ocyon 
Bio PR, Inc., Aguadilla, PUERTO RICO; PSC Biotech Corp., Pomona, CA; 
Regis Technologies, Inc., Morton Grove, IL; Resilience Government 
Services, Alachua, FL; Riya Interactive, Inc., Chicago, IL; SEQENS, 
Devens, MA; Sanofi Pasteur, Inc., Swiftwater, PA; Slingshot 
Biosciences, Inc., Emeryville, CA; Smart World LLC dba Steri-Tek, 
Fremont, CA; TR Processing LLC, Golden Valley, MN; The Conafay Group, 
Washington, DC; USAntibiotics LLC, Bristol, TN; Varda Space Industries, 
Inc., El Segundo, CA.
    Consistent with 15 U.S.C. 4301(a)(6)(C), (E) and (F), the general 
areas of BioMaP Consortium's planned activities are to engage the 
biopharmaceutical industrial base to enable targeted development 
expertise, address new and emerging biopharmaceutical technologies that 
enhance existing capabilities, as well as prepare for potential 
response to emerging pathogens with pandemic potential.

Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-07947 Filed 4-15-24; 8:45 am]
BILLING CODE P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.